The abnormal expression of CREBZF is closely correlated to cancer progression and prognosis; for example, high CREBZF expression predicts poor OS and/or progression-free survival in patient with ovarian cancer (30), and it is considered as a biomarker for the pathological progression of GC (31). Here, CREBZF is linked to gastric cancer.